NL301020I1 - - Google Patents
Info
- Publication number
- NL301020I1 NL301020I1 NL301020C NL301020C NL301020I1 NL 301020 I1 NL301020 I1 NL 301020I1 NL 301020 C NL301020 C NL 301020C NL 301020 C NL301020 C NL 301020C NL 301020 I1 NL301020 I1 NL 301020I1
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002010447 | 2002-01-18 | ||
| JP2002010413 | 2002-01-18 | ||
| PCT/JP2003/000270 WO2003062233A1 (en) | 2002-01-18 | 2003-01-15 | 2-acylaminothiazole derivative or salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301020I1 true NL301020I1 (enExample) | 2019-12-16 |
| NL301020I2 NL301020I2 (nl) | 2020-04-21 |
Family
ID=27615666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301020C NL301020I2 (nl) | 2002-01-18 | 2019-12-11 | Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7638536B2 (enExample) |
| EP (2) | EP1466912B1 (enExample) |
| JP (2) | JP4120586B2 (enExample) |
| KR (1) | KR101010905B1 (enExample) |
| CN (1) | CN1319967C (enExample) |
| BE (1) | BE2019C547I2 (enExample) |
| CA (1) | CA2472711C (enExample) |
| CY (2) | CY1114169T1 (enExample) |
| DK (1) | DK1466912T3 (enExample) |
| ES (2) | ES2610611T3 (enExample) |
| FR (1) | FR19C1072I2 (enExample) |
| HU (1) | HUS1900052I1 (enExample) |
| LU (1) | LUC00137I2 (enExample) |
| NL (1) | NL301020I2 (enExample) |
| PT (1) | PT1466912E (enExample) |
| SI (1) | SI1466912T1 (enExample) |
| WO (1) | WO2003062233A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI284639B (en) * | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| JP4120586B2 (ja) | 2002-01-18 | 2008-07-16 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| US7501417B2 (en) * | 2002-03-13 | 2009-03-10 | Janssen Pharmaceutica, N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| JP4317818B2 (ja) * | 2002-09-30 | 2009-08-19 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体の新規な塩 |
| US7361658B2 (en) | 2003-07-17 | 2008-04-22 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| CN103130739B (zh) | 2003-08-12 | 2015-09-16 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的化合物 |
| JP4638355B2 (ja) * | 2003-12-26 | 2011-02-23 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| AU2004321997A1 (en) * | 2004-07-06 | 2006-02-09 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
| ES2359840T5 (es) * | 2004-09-20 | 2015-03-25 | Xenon Pharmaceuticals Inc. | Derivados de piridina para inhibición de estearoil-CoA-desaturasa humana |
| KR100958337B1 (ko) * | 2004-10-25 | 2010-05-17 | 리간드 파마슈티칼스 인코포레이티드 | 트롬보포이에틴 활성 조절 화합물 및 방법 |
| TWI351954B (en) * | 2004-12-08 | 2011-11-11 | Nissan Chemical Ind Ltd | Heterocyclic compounds and thrombopoietin receptor |
| JP4973192B2 (ja) | 2004-12-14 | 2012-07-11 | 日産化学工業株式会社 | アミド化合物及びトロンボポエチンレセプター活性化剤 |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| JP4665769B2 (ja) * | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| EP1894930A4 (en) * | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | THIAZOLE DERIVATIVE |
| WO2007036769A1 (en) * | 2005-07-05 | 2007-04-05 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
| WO2007004038A1 (en) * | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
| CA2614726A1 (en) * | 2005-07-13 | 2007-01-18 | Astrazeneca Ab | New pyridine analogues |
| CA2609319C (en) * | 2005-07-15 | 2014-02-04 | Nissan Chemical Industries, Ltd. | Thiophene compounds and thrombopoietin receptor activators |
| US7960425B2 (en) | 2005-07-20 | 2011-06-14 | Nissan Chemical Industries, Ltd. | Pyrazole compounds and thrombopoietin receptor activators |
| WO2007052808A1 (ja) | 2005-11-07 | 2007-05-10 | Nissan Chemical Industries, Ltd. | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
| WO2007054783A2 (en) * | 2005-11-08 | 2007-05-18 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
| EP2025671A4 (en) | 2006-06-07 | 2011-04-06 | Nissan Chemical Ind Ltd | NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR |
| AU2007284644B2 (en) * | 2006-08-08 | 2011-09-01 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
| JP5164510B2 (ja) * | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| CN103396313B (zh) | 2007-07-31 | 2015-05-13 | 盐野义制药株式会社 | 含有具血小板生成素受体激动作用的光学活性化合物的药物组合物及其中间体 |
| ES2331220B1 (es) * | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| BRPI0818346A2 (pt) * | 2007-10-09 | 2015-04-07 | Univ Pennsylvania | Morte de células de leucemia mielóide aguda humana pelo agonista de receptor de trombopoietina(tpora) |
| EA201001358A1 (ru) * | 2008-02-25 | 2011-04-29 | Мерк Патент Гмбх | Активаторы глюкокиназы |
| US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
| US8680150B2 (en) * | 2009-05-28 | 2014-03-25 | Ligand Pharmaceuticals, Inc. | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors |
| WO2011019990A1 (en) * | 2009-08-14 | 2011-02-17 | Eisai, Inc. | Use of e5501 for stimulating platelet production |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JP2014144916A (ja) | 2011-08-03 | 2014-08-14 | Astellas Pharma Inc | ２−アシルアミノチアゾール化合物の結晶 |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9212147B2 (en) | 2011-11-15 | 2015-12-15 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
| JPWO2013146754A1 (ja) * | 2012-03-27 | 2015-12-14 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| BR112015022202A2 (pt) | 2013-03-14 | 2017-07-18 | Dart Neuroscience Cayman Ltd | compostos substituídos de naftiridina e quinolina como inibidores da mao |
| CN105518005B (zh) | 2013-07-02 | 2018-07-20 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
| CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
| MX370140B (es) | 2014-06-06 | 2019-12-03 | Astellas Pharma Inc | Derivado de 2-acilaminotiazol o sal del mismo. |
| MX2017002500A (es) * | 2014-08-26 | 2017-05-23 | Astellas Pharma Inc | Derivado de 2-aminotiazol o sal del mismo. |
| WO2016068270A1 (ja) | 2014-10-31 | 2016-05-06 | 日産化学工業株式会社 | リガンド結合繊維及び当該繊維を用いた細胞培養基材 |
| CN109415371B (zh) * | 2016-09-08 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 一种2-酰氨基噻唑衍生物及其制备方法与用途 |
| CN106749226B (zh) * | 2017-03-15 | 2019-12-20 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
| CN107383000A (zh) * | 2017-08-07 | 2017-11-24 | 瑞阳制药有限公司 | 血小板增多剂的制备方法 |
| WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
| RU2709496C1 (ru) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Способ получения аватромбопага |
| CN110586047B (zh) * | 2019-10-08 | 2022-03-11 | 辽宁工业大学 | 一种用于吸附铅离子的改性双醛淀粉制备方法 |
| CN111620863A (zh) * | 2020-06-23 | 2020-09-04 | 苏州明锐医药科技有限公司 | 阿曲波帕的制备方法 |
| CN114957236A (zh) * | 2021-02-25 | 2022-08-30 | 南京正大天晴制药有限公司 | 一种2-酰基氨基噻唑类化合物的制备方法 |
| CN115057854A (zh) * | 2022-04-19 | 2022-09-16 | 河北常山生化药业股份有限公司 | 马来酸阿伐曲泊帕中间体的制备方法 |
| CN115477645A (zh) * | 2022-09-28 | 2022-12-16 | 湖南先施制药有限公司 | 马来酸阿伐曲泊帕系列杂质及其制备方法和应用 |
| CN116813609A (zh) * | 2023-07-03 | 2023-09-29 | 上海天鹤年药业有限公司 | 一种阿伐曲泊帕的制备方法 |
| WO2025132929A2 (en) | 2023-12-19 | 2025-06-26 | Synthon B.V | Salts of avatrombopag |
| WO2025133011A1 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V | Formulation comprising form b of avatrombopag maleate |
| EP4660195A1 (en) | 2024-06-05 | 2025-12-10 | Noucor Health S.A. | Crystalline forms of avatrombopag maleate and preparation thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
| TW205041B (enExample) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
| JPH078863B2 (ja) | 1989-09-21 | 1995-02-01 | 久光製薬株式会社 | 新規なジフェニルチアゾール誘導体 |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| JPH03199451A (ja) | 1989-12-26 | 1991-08-30 | Asahi Chem Ind Co Ltd | エアージェットルーム用筬 |
| FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| JP3173876B2 (ja) | 1992-06-26 | 2001-06-04 | 日本パイオニクス株式会社 | 有害ガスの検知システム |
| AU7545894A (en) | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| KR970701174A (ko) | 1994-02-10 | 1997-03-17 | 오노다 마사요시 | 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same) |
| DE69629341T2 (de) * | 1995-03-09 | 2004-06-09 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazolderivate |
| US5750540A (en) * | 1995-04-28 | 1998-05-12 | Banyu Pharmaceutical Co., Ltd. | 1,4-di-substituted piperidine derivatives |
| PT885242E (pt) * | 1995-06-07 | 2008-06-18 | Glaxo Group Ltd | Péptidos e compostos que se ligam a um receptor de trombopoietina |
| US5963666A (en) * | 1995-08-18 | 1999-10-05 | International Business Machines Corporation | Confusion matrix mediated word prediction |
| EP0798304B1 (en) * | 1995-10-17 | 2003-03-12 | Suntory Limited | Remedies for thrombocytopenia |
| TR199802401T2 (xx) | 1996-05-22 | 1999-03-22 | Smithkline Beecham Corporation | Peptid olmayan G-CSF mimetikleri. |
| AU4136197A (en) | 1996-09-09 | 1998-03-26 | Kyowa Hakko Kogyo Co. Ltd. | Pyrrolocarbazole derivatives |
| US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| JPH10212289A (ja) | 1997-01-31 | 1998-08-11 | Kyowa Hakko Kogyo Co Ltd | ピロロフェナンスリジン誘導体 |
| WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| JPH11152276A (ja) * | 1997-11-20 | 1999-06-08 | Hokuriku Seiyaku Co Ltd | ベンゾジアゼピン誘導体 |
| JP2000044562A (ja) | 1998-07-31 | 2000-02-15 | Kyowa Hakko Kogyo Co Ltd | ピロロフタルイミド誘導体 |
| AU762245B2 (en) | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| EP1133291B1 (en) * | 1998-11-17 | 2006-01-11 | Smithkline Beecham Corporation | Cyclic polyamines for treating thrombocytopenia |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| KR20020069183A (ko) | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| CN100370975C (zh) | 2000-12-18 | 2008-02-27 | 株式会社医药分子设计研究所 | 炎症性细胞因子产生游离抑制剂 |
| EP1353674A1 (en) | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
| US20040077697A1 (en) * | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| EP1364949A4 (en) | 2001-02-02 | 2005-11-23 | Takeda Pharmaceutical | JNK INHIBITOR |
| JP4120586B2 (ja) | 2002-01-18 | 2008-07-16 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| WO2003075921A2 (en) | 2002-03-05 | 2003-09-18 | Transtech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| WO2003084544A2 (en) | 2002-04-04 | 2003-10-16 | Cv Therapeutics, Inc. | Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis |
| AU2003242124A1 (en) | 2002-06-11 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of neurodegenerative diseases |
| EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
| JP4317818B2 (ja) | 2002-09-30 | 2009-08-19 | アステラス製薬株式会社 | ２−アシルアミノチアゾール誘導体の新規な塩 |
| EP1594847A2 (en) | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| US20040235834A1 (en) * | 2003-03-25 | 2004-11-25 | Farmer Luc J. | Thiazoles useful as inhibitors of protein kinases |
| US7361658B2 (en) * | 2003-07-17 | 2008-04-22 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| CN103130739B (zh) * | 2003-08-12 | 2015-09-16 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的化合物 |
| WO2007054783A2 (en) * | 2005-11-08 | 2007-05-18 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
| AU2007284644B2 (en) | 2006-08-08 | 2011-09-01 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
-
2003
- 2003-01-15 JP JP2003562111A patent/JP4120586B2/ja not_active Expired - Lifetime
- 2003-01-15 CN CNB038044579A patent/CN1319967C/zh not_active Expired - Lifetime
- 2003-01-15 DK DK03700571.7T patent/DK1466912T3/da active
- 2003-01-15 ES ES11154632.1T patent/ES2610611T3/es not_active Expired - Lifetime
- 2003-01-15 CA CA2472711A patent/CA2472711C/en not_active Expired - Lifetime
- 2003-01-15 SI SI200332274T patent/SI1466912T1/sl unknown
- 2003-01-15 US US10/500,964 patent/US7638536B2/en active Active
- 2003-01-15 EP EP03700571.7A patent/EP1466912B1/en not_active Expired - Lifetime
- 2003-01-15 ES ES03700571T patent/ES2416304T3/es not_active Expired - Lifetime
- 2003-01-15 EP EP11154632.1A patent/EP2314586B1/en not_active Expired - Lifetime
- 2003-01-15 PT PT37005717T patent/PT1466912E/pt unknown
- 2003-01-15 WO PCT/JP2003/000270 patent/WO2003062233A1/ja not_active Ceased
- 2003-01-15 KR KR1020047010846A patent/KR101010905B1/ko not_active Expired - Lifetime
-
2008
- 2008-02-04 JP JP2008023950A patent/JP4844574B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-10 US US12/615,968 patent/US8338429B2/en not_active Expired - Fee Related
- 2009-11-10 US US12/615,979 patent/US20100222329A1/en not_active Abandoned
-
2012
- 2012-11-15 US US13/677,520 patent/US8765764B2/en not_active Expired - Lifetime
-
2013
- 2013-07-24 CY CY20131100629T patent/CY1114169T1/el unknown
-
2019
- 2019-11-06 BE BE2019C547C patent/BE2019C547I2/fr unknown
- 2019-11-12 LU LU00137C patent/LUC00137I2/fr unknown
- 2019-12-06 FR FR19C1072C patent/FR19C1072I2/fr active Active
- 2019-12-11 NL NL301020C patent/NL301020I2/nl unknown
- 2019-12-11 HU HUS1900052C patent/HUS1900052I1/hu unknown
- 2019-12-17 CY CY2019045C patent/CY2019045I2/el unknown